1. Home
  2. AADI vs FLUX Comparison

AADI vs FLUX Comparison

Compare AADI & FLUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AADI
  • FLUX
  • Stock Information
  • Founded
  • AADI 2011
  • FLUX N/A
  • Country
  • AADI United States
  • FLUX United States
  • Employees
  • AADI N/A
  • FLUX N/A
  • Industry
  • AADI Biotechnology: Pharmaceutical Preparations
  • FLUX Industrial Machinery/Components
  • Sector
  • AADI Health Care
  • FLUX Miscellaneous
  • Exchange
  • AADI Nasdaq
  • FLUX Nasdaq
  • Market Cap
  • AADI 49.0M
  • FLUX 51.4M
  • IPO Year
  • AADI N/A
  • FLUX N/A
  • Fundamental
  • Price
  • AADI $2.11
  • FLUX $2.19
  • Analyst Decision
  • AADI Hold
  • FLUX Strong Buy
  • Analyst Count
  • AADI 3
  • FLUX 4
  • Target Price
  • AADI $1.75
  • FLUX $9.50
  • AVG Volume (30 Days)
  • AADI 114.7K
  • FLUX 61.0K
  • Earning Date
  • AADI 11-06-2024
  • FLUX 11-26-2024
  • Dividend Yield
  • AADI N/A
  • FLUX N/A
  • EPS Growth
  • AADI N/A
  • FLUX N/A
  • EPS
  • AADI N/A
  • FLUX N/A
  • Revenue
  • AADI $25,070,000.00
  • FLUX $63,850,000.00
  • Revenue This Year
  • AADI $8.10
  • FLUX N/A
  • Revenue Next Year
  • AADI $8.54
  • FLUX $13.51
  • P/E Ratio
  • AADI N/A
  • FLUX N/A
  • Revenue Growth
  • AADI 7.80
  • FLUX N/A
  • 52 Week Low
  • AADI $1.21
  • FLUX $2.10
  • 52 Week High
  • AADI $5.70
  • FLUX $5.86
  • Technical
  • Relative Strength Index (RSI)
  • AADI 56.23
  • FLUX 28.90
  • Support Level
  • AADI $1.98
  • FLUX $2.30
  • Resistance Level
  • AADI $2.40
  • FLUX $2.89
  • Average True Range (ATR)
  • AADI 0.11
  • FLUX 0.23
  • MACD
  • AADI 0.01
  • FLUX -0.04
  • Stochastic Oscillator
  • AADI 36.96
  • FLUX 9.57

About AADI Aadi Bioscience Inc.

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

About FLUX Flux Power Holdings Inc.

Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.

Share on Social Networks: